CLINICAL_TRIALS
trial_result
· 2021-05-04
Clinical Trial Update: A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis [Phase 2]
Summary
Phase 2 trial of lebrituzumab (LY3650150) in moderate-to-severe atopic dermatitis completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2021-05-04